Back to search results

NOORI Study: SmartMatch for Rare Gynecologic Cancers

This study, called NOORI, is looking at how easy it is to use a special analysis called SmartMatch to help find treatment options for advanced rare gynecologic cancers. These are cancers of the female reproductive system that have spread (metastatic) or cannot be removed by surgery (unresectable). Researchers want to see if they can get enough fresh tumor tissue from standard surgeries or biopsies to use SmartMatch. The main goal is to see how many participants get at least one treatment recommendation from SmartMatch within 4 weeks of their tissue being collected. This study is for women aged 18 and older who have a confirmed rare gynecologic cancer that is metastatic, unresectable, or needs more treatment. The study is currently observational, meaning you would have your medical records reviewed and tissue samples collected as part of your regular care.

Study design
This is an observational study with a planned enrollment of 30 participants. It is not a drug trial.
What's involved
You would have tissue samples collected from a standard surgery or biopsy, and your medical records would be reviewed.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 36 months from enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07731880

Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers

Not Yet Recruiting
Not specifiedAges 18+Observational
Fred Hutchinson Cancer Center
~30 participants
Updated 2026-07-28 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants for whom SmartMatch generates at least one actionable treatment recommendation that is presented at the PMTB within 4 weeks (≤ 28 days) of fresh tissue acquisition
Measured over From enrollment up to 36 months

Conditions

Malignant Female Reproductive System Neoplasm
Metastatic Malignant Female Reproductive System Neoplasm
Unresectable Malignant Female Reproductive System Neoplasm

Explore related trials

Female Reproductive System NeoplasmMalignant Female Reproductive System Neoplasm

Where it's being run

1 sites across 1 states
Washington1

Study leadership

  • Kalyan Banda, MD · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Who to contact

Kalyan Banda, MD
[email protected]
206-606-2222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Histologically confirmed rare gynecologic malignancy, including but not limited to those listed
Metastatic or unresectable disease, OR disease for which additional systemic therapy is indicated
Fresh tumor tissue available from a SOC surgical procedure or biopsy that in the judgment of the treating team will yield adequate viable tumor for SmartMatch analysis
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Adequate organ function to receive systemic therapy as determined by the treating oncologist (protocol does not specify thresholds because therapy is not mandated)
Ability to understand and willingness to sign informed consent
Willingness to allow data abstraction from the electronic health record for study endpoints

Exclusion

Lack of tumor tissue suitable for SmartMatch analysis
Purely borderline tumors or benign ovarian/uterine neoplasms
Any condition that, in the opinion of the treating oncologist or PI, would interfere with receiving systemic therapy
Inability to provide informed consent or comply with study procedures

What this trial measures

  • Proportion of participants for whom SmartMatch generates at least one actionable treatment recommendation that is presented at the PMTB within 4 weeks (≤ 28 days) of fresh tissue acquisitionFrom enrollment up to 36 months

    An actionable recommendation is defined as: 1. FDA-approved therapy for any indication or available clinical trial; 2. Predicted to have activity by SmartMatch functional precision medicine (FPM) and/or genomics; 3. Endorsed by PMTB as clinically reasonable.